Calibration method of analyte monitoring system, storage medium and related system

Through the analyte monitoring system, data is obtained independently and calibration based on classification and waveform characteristics, the problem of inaccurate readings caused by changes in sensor properties is solved, convenient and efficient glucose concentration monitoring is achieved, and user experience and system autonomy is improved.

CN118986345APending Publication Date: 2024-11-22SHENZHEN SISENSING TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310575516.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-19
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

During use, the changes in sensor properties of the existing glucose monitoring system lead to inaccurate readings, requiring external equipment to be calibrated, but the process is cumbersome and inconvenient for users.

Method used

Data of the target object is obtained through the analyte monitoring system, the predicted baseline and actual baseline are determined based on classification and waveform characteristics, and the concentration value reading is automatically calibrated, reducing dependence on external devices, and improving calibration convenience and integration.

Benefits of technology

The glucose concentration monitoring based on autonomous data calibration is realized, which improves the accuracy and user experience of readings, reduces dependence on external devices, and enhances the autonomy and convenience of the system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986345A_ABST
    Figure CN118986345A_ABST
Patent Text Reader

Abstract

The invention discloses a calibration method of an analyte monitoring system, a storage medium and a related system. The calibration method comprises the following steps: acquiring first data of a target object; determining the classification of the target object based on the first data; determining a prediction baseline of the target object based on classification; acquiring second data of the target object; determining an actual baseline of the target object based on the second data; the concentration value readings within the third time are calibrated based on the predicted baseline and the actual baseline. Therefore, the concentration value reading is calibrated based on the characteristics of the target object, the dependence on external calibration equipment can be reduced, and the calibration convenience can be improved. In addition, data obtained by the analyte monitoring system is used for calibration, and the integration degree of the method and the analyte monitoring system can be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates generally to the field of medical devices, and more particularly to a calibration method, storage medium, and related system for an analyte monitoring system. Background Art

[0002] Diabetes is a disorder of the metabolism of a series of substances in the body, such as sugar, protein, fat, water and electrolytes. If it is not well controlled, it may cause some complications, such as ketoacidosis, lactic acidosis, chronic renal failure and retinopathy. For diabetic patients, if the concentration of glucose can be monitored more accurately and corresponding measures can be taken, it will help control the occurrence of complications.

[0003] Typically, a glucose monitoring system for sensing glucose concentration generally includes an implanted glucose sensor. The glucose sensor can be placed subcutaneously to monitor the current generated by the glucose reaction in the subcutaneous tissue fluid, and the glucose monitoring system can monitor the change of glucose concentration in the tissue fluid based on the current.

[0004] However, when the glucose sensor is in an in vivo environment, some properties of the glucose sensor (such as sensor sensitivity) will change during use, resulting in inaccurate glucose concentration readings obtained by the glucose monitoring system. Prior art glucose monitoring systems use fingertip blood glucose devices to calibrate glucose concentration readings when in use. However, the method of calibrating the glucose concentration readings of the glucose monitoring system with a fingertip blood glucose device requires carrying a fingertip blood glucose device, and the blood collection process will produce a certain degree of pain, which may cause inconvenience to the user during calibration and affect the user experience. Summary of the invention

[0005] The present disclosure is proposed in view of the above-mentioned state of the prior art, and its purpose is to provide a calibration method, storage medium and related system of an analyte monitoring system that can reduce dependence on external calibration equipment and improve the convenience of calibration.

[0006] To this end, the first aspect of the present disclosure provides a calibration method for an analyte monitoring system, the calibration method comprising: acquiring first data of a target object, the first data comprising concentration value readings of an analyte that vary with time and obtained by the analyte monitoring system within a first time; determining a category to which the target object belongs based on the first data; determining a predicted baseline of the target object based on the classification; acquiring second data of the target object, the second data comprising concentration value readings of an analyte that vary with time and obtained by the analyte monitoring system within a second time, the second time being after the first time; determining an actual baseline of the target object based on the second data; and calibrating the concentration value readings within a third time based on the predicted baseline and the actual baseline, the third time being after the second time.

[0007] In the first aspect of the present disclosure, the concentration value reading of the analyte of the analyte monitoring system can be calibrated based on the classification to which the target object belongs. In this case, the concentration value reading is calibrated based on the classification to which the target object itself belongs, which can reduce the dependence on external calibration equipment, thereby improving the convenience of calibration. In addition, the present disclosure uses data obtained by the analyte monitoring system for calibration, which can improve the integration of the present disclosure with the analyte monitoring system.

[0008] In addition, in the calibration method involved in the first aspect of the present disclosure, optionally, the classification is related to the control of the analyte concentration of the target object. In this case, classifying the target object based on the control of the analyte concentration can better fit the concentration value distribution of the analyte of the target object when calibrating the concentration value reading of the analyte according to the classification, thereby more effectively calibrating the concentration value reading.

[0009] In addition, in the calibration method involved in the first aspect of the present disclosure, optionally, the classification includes normal concentration, low concentration, too low concentration and high concentration. Thus, the concentration value reading of the analyte can be calibrated based on a finer-grained classification.

[0010] In addition, in the calibration method involved in the first aspect of the present disclosure, optionally, the classification is determined based on the waveform characteristics of the first data. In this case, the control situation of the analyte concentration of the target object can be determined based on the waveform characteristics and the classification to which the target object belongs can be obtained based on the control situation.

[0011] In addition, in the calibration method involved in the first aspect of the present disclosure, optionally, the waveform characteristics include rising amplitude, falling amplitude, rising rate and falling rate, and the waveform characteristics are related to eating. Thus, the classification can be determined based on the effect of eating on the analyte concentration of the target object.

[0012] In addition, in the calibration method involved in the first aspect of the present disclosure, optionally, it also includes updating the predicted baseline at a regular interval, updating the predicted baseline in response to an update request, or updating the predicted baseline in response to the difference between the waveform characteristics of the second data and the waveform characteristics of the first data being greater than a preset degree. In this case, updating the predicted baseline can make the calibration adapt to the change in the concentration value trend of the target object analyte, and can improve the accuracy of the calibration.

[0013] In addition, in the calibration method involved in the first aspect of the present disclosure, optionally, the actual baseline is determined based on the concentration value readings in at least one reference period in which the fluctuation amplitude in the second time is smaller than a preset amplitude, thereby obtaining a relatively stable actual baseline.

[0014] In addition, in the calibration method involved in the first aspect of the present disclosure, optionally, in the calibration, the adjustment direction and adjustment range of the concentration value reading within the third time are determined based on the deviation between the actual baseline and the predicted baseline. In this case, the deviation-based method is relatively simple and can more easily determine the adjustment direction and adjustment range.

[0015] In addition, in the calibration method involved in the first aspect of the present disclosure, optionally, when an abnormal analyte concentration event is identified within the third time, an upper limit or a lower limit is set for the range of the adjustment amplitude. In this case, setting an upper limit or a lower limit for the range of the adjustment amplitude for an abnormal analyte concentration event can improve the sensitivity to the abnormal analyte concentration event.

[0016] In addition, in the calibration method involved in the first aspect of the present disclosure, optionally, when the abnormal analyte concentration event is an event in which the analyte concentration value reading within the third time is lower than a preset concentration value, an upper limit is set for the range of the adjustment amplitude. Thus, the sensitivity to the situation in which the analyte concentration is too low can be improved.

[0017] In addition, in the calibration method involved in the first aspect of the present disclosure, optionally, the analyte includes one or more of blood ketones, acetylcholine, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase, creatine, creatinine, DNA, fructosamine, glucose, glutamine, growth hormone, hormone, ketone body, lactate, peroxide, prostate specific antigen, prothrombin, RNA, thyroid stimulating hormone and troponin. Thus, the present disclosure can be applied to the calibration of concentration value readings of multiple analytes.

[0018] The second aspect of the present disclosure further provides a storage medium, wherein the storage medium stores computer program instructions, and when a processor runs the computer program instructions, the calibration method as described in any one of the first aspects of the present disclosure is executed. In this case, the present disclosure can be applied to electronic devices that can run computer programs.

[0019] The third aspect of the present disclosure further provides an analyte monitoring system, comprising an analyte sensor and an electronic device connected to the analyte sensor, wherein the electronic device comprises a processor and a storage medium as described in the second aspect of the present disclosure. In this case, the present disclosure can be applied to an analyte monitoring system that can run a computer program, thereby enabling the analyte monitoring system to obtain more accurate analyte concentration information.

[0020] According to the present disclosure, a calibration method, storage medium and related system of an analyte monitoring system are provided, which can reduce the dependence on external calibration equipment and improve the convenience of calibration. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] The present disclosure will now be explained in further detail by way of example only with reference to the accompanying drawings, in which:

[0022] Figure 1 is a schematic diagram showing an application scenario of the glucose monitoring system involved in the example of the present disclosure.

[0023] Figure 2 Schematic diagram showing the structure of the glucose sensor involved in the example of the present disclosure.

[0024] Figure 3 Schematic diagram showing the structure of the working electrode of the glucose sensor involved in the example of the present disclosure.

[0025] Figure 4 is a general flow chart showing a calibration method of a glucose monitoring system according to an example of the present disclosure.

[0026] Figure 5 is a schematic flowchart showing the process of determining waveform features involved in the example of the present disclosure.

[0027] Figure 6 Schematic diagram showing a glucose concentration value curve of a population with normal glucose concentration control involved in the example of the present disclosure.

[0028] Figure 7 is a schematic diagram showing a glucose concentration value reading for determining an actual baseline of a user according to an example of the present disclosure.

[0029] Figure 8 is a schematic flow chart showing the calibration of concentration value readings based on predicted baseline and actual baseline involved in examples of the present disclosure.

[0030] Description of reference numerals:

[0031] Glucose monitoring system…1, glucose sensor…2, working electrode…10, base layer…110, sensing layer…120, polymer membrane layer…130, diffusion control layer…131, anti-interference layer…132, anti-biofouling layer…133, reference electrode…20, counter electrode…30, substrate…S, first contact…40, second contact…50, third contact…60, electronic system…3. DETAILED DESCRIPTION

[0032] Hereinafter, the preferred embodiments of the present disclosure will be described in detail with reference to the accompanying drawings. In the following description, the same symbols are assigned to the same components, and repeated descriptions are omitted. In addition, the accompanying drawings are only schematic diagrams, and the ratio of the dimensions of the components or the shapes of the components may be different from the actual ones.

[0033] It should be noted that the terms "including" and "having" and any variations thereof in the present disclosure, such as a process, method, system, product or device that includes or has a series of steps or units, are not necessarily limited to those steps or units clearly listed, but may include or have other steps or units that are not clearly listed or inherent to these processes, methods, products or devices.

[0034] The inventor has found through research that when calibrating an analyte monitoring system, the concentration value reading can be calibrated based on the analyte concentration value data obtained by the analyte monitoring system and the characteristics of the target object (e.g., human body) itself. To this end, the present disclosure provides a calibration method for an analyte monitoring system and a related system. The calibration method for an analyte monitoring system involved in the examples of the present disclosure may also be referred to as a calibration method or an adjustment method.

[0035] In some examples, an analyte monitoring system is a system for obtaining information about the concentration of some analytes in the human body (also referred to as a concentration value reading of the analyte). In some examples, in some medical situations, such as surgery, hospitalization, and some diseases involving abnormal distribution of substances in the body (such as diabetes), it is necessary to use an analyte monitoring system (such as a glucose sensor) to continuously monitor the concentration of related substances in the human body over a period of time to control the analyte. In some examples, the components of the analyte monitoring system include an analyte sensor.

[0036] In some examples, the analyte monitoring system obtains the concentration value reading of the analyte by the analyte sensor participating in the chemical reaction of the relevant analyte in the human body to obtain the relevant output signal, and after the output signal is transmitted to the signal processing system connected to the analyte sensor (such as an electronic device in the analysis monitoring system), the signal processing system converts the output signal of the analyte sensor into the concentration value reading of the analyte. In this way, the analyte concentration in the human body can be monitored.

[0037] In some examples, during the use of the analyte monitoring system, the properties of the analyte sensor (e.g., sensor sensitivity) may change, causing the analyte concentration information (also referred to as the analyte concentration value reading) obtained by the analyte monitoring system to become inaccurate with use. In response to this situation, the prior art generally uses information obtained by additional equipment to calibrate the analyte monitoring system. For example, for a glucose monitoring system, the glucose concentration value reading measured by a fingertip blood glucose device is generally used to calibrate the glucose monitoring system.

[0038] In some examples, in the calibration method involved in the examples of the present disclosure, the analyte may include one or more of blood ketones, acetylcholine, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase, creatine, creatinine, DNA, fructosamine, glucose, glutamine, growth hormone, hormone, ketone body, lactate, peroxide, prostate specific antigen, prothrombin, RNA, thyroid stimulating hormone and troponin. Thus, the present disclosure can be applied to the calibration of concentration value readings of multiple analytes.

[0039] For ease of understanding, the analyte monitoring system is introduced below by taking the glucose monitoring system as an example. However, the specific embodiments of the present disclosure are not limited thereto, and unless there is a contradiction, the relevant description of the glucose monitoring system is also applicable to the analyte monitoring system. For example, glucose and analyte, glucose concentration and analyte concentration, glucose monitoring system and analyte monitoring system can be replaced with each other if there is no contradiction.

[0040] Figure 1 is a schematic diagram showing the usage status of the glucose monitoring system 1 involved in the example of the present disclosure.

[0041] In some examples, such as Figure 1 As shown, the glucose monitoring system 1 may include a glucose sensor 2 and an electronic system 3 connected to the glucose sensor 2. By implanting the glucose sensor 2 of the glucose monitoring system 1 into a human body, such as under the skin of a human body, the glucose sensor 2 contacts the tissue fluid or blood on the body surface and participates in the chemical reaction of glucose in the tissue fluid or blood to obtain an output signal. After the output signal is transmitted to the electronic system 3, the electronic system 3 converts the output signal into a glucose concentration value reading.

[0042] In some examples, the output signal of the glucose sensor 2 can be an electrical signal (e.g., a current signal). In some examples, the glucose monitoring system 1 is implanted in an arm. In other examples, the glucose monitoring system 1 can also be implanted in the abdomen, waist, leg, etc.

[0043] In some examples, the glucose sensor 2 may be disposed in a puncture needle (not shown), and the glucose sensor 2 may be detachable from the puncture needle. When the glucose monitoring system 1 is worn, the puncture needle wrapped with the glucose sensor 2 may be inserted into tissue, and then the puncture needle may be pulled out and separated from the glucose sensor 2, so that the glucose sensor 2 is placed subcutaneously.

[0044] In some examples, the glucose sensor 2 can be inserted 3 mm to 20 mm under the skin. In some examples, the depth of the glucose sensor 2 inserted under the skin is determined according to the insertion position. When the fat layer is thicker, the insertion is deeper, such as the abdomen of the human body, and the insertion depth can be about 10 mm to 15 mm. When the fat layer is thinner, the insertion is shallower, such as the arm, and the insertion depth can be about 5 mm to 10 mm.

[0045] In some examples, the glucose sensor 2 may have an electrode capable of participating in a chemical reaction of glucose. In some examples, the electrode may have a film layer. In some examples, the film layer may have a multilayer structure. In some examples, at least one layer of the multilayer structure may have a glucose reaction enzyme capable of participating in a glucose reaction.

[0046] Figure 2 is a schematic diagram showing the structure of the glucose sensor 2 involved in the example of the present disclosure.

[0047] In some examples, such as Figure 2 As shown, the glucose sensor 2 may include a substrate S, a working electrode 10 disposed on the substrate S, a reference electrode 20 and a counter electrode 30 .

[0048] In addition, the glucose sensor 2 may further include a first contact 40 connected to the working electrode 10 via a lead, a second contact 50 connected to the reference electrode 20 via a lead, and a third contact 60 connected to the counter electrode 30 via a lead. In some examples, the glucose sensor 2 may be connected to the electronic system 3 via the first contact 40, the second contact 50, and the third contact 60, and the output signal may be transmitted to the electronic system 3 via the first contact 40, the second contact 50, and the third contact 60. In this case, the connection and signal transmission between the glucose sensor 2 and the electronic device can be facilitated. In addition, the contact connection has higher flexibility.

[0049] In addition, in some examples, the electronic system 3 can be arranged on the surface of the human body. In some examples, the electronic system 3 can process the output signal to obtain the glucose concentration value reading. In other examples, the electronic system 3 may not obtain the glucose concentration value reading. For example, the electronic system 3 can store the output signal and transmit the stored output signal to the signal processing system.

[0050] Figure 3 Schematic diagram showing the structure of the working electrode 10 of the glucose sensor 2 involved in the example of the present disclosure.

[0051] In some examples, such as Figure 3 As shown, the working electrode 10 may include a substrate layer 110, a sensing layer 120, and a polymer film layer 130. In some examples, the substrate layer 110, the sensing layer 120, and the polymer film layer 130 may be stacked in sequence. In some examples, the polymer film layer 130 may include a diffusion control layer 131, an anti-interference layer 132, and an anti-biofouling layer 133.

[0052] In some examples, the sensing layer 120 may be disposed on the base layer 110 . That is, the sensing layer 120 may be disposed between the base layer 110 and the polymer film layer 130 .

[0053] In some examples, the sensing layer 120 can be formed on the base layer 110 by coating a sensing reagent and can chemically react with glucose. In some examples, the sensing reagent can include a glucose-responsive enzyme. In some examples, the glucose-responsive enzyme can be glucose oxidase or glucose dehydrogenase.

[0054] In some examples, under the action of glucose-responsive enzyme, the sensing layer 120 can participate in the electrochemical reaction (e.g., redox reaction) of glucose in the tissue fluid environment of the human body to form electron transfer, thereby converting the glucose concentration information in the tissue fluid into an electrical signal (i.e., a current signal). In some examples, the activity of glucose-responsive enzyme is affected by the ambient temperature, and there is a strong correlation between the activity and the ambient temperature.

[0055] In some examples, the glucose-responsive enzyme in the sensing layer 120 of the working electrode 10 of the glucose sensor 2 may be affected by, for example, temperature or other substances in the environment during use, causing the activity of the glucose-responsive enzyme to change or peel off from the sensing layer 120, thereby reducing the sensitivity of the glucose sensor 2. In some examples, the membrane layer and the material conducting the current signal in the working electrode 10 may age during use, thereby reducing the sensitivity of the glucose sensor 2 or causing signal attenuation.

[0056] Therefore, during the use of the glucose monitoring system 1 , it is necessary to consider calibrating the glucose concentration value reading obtained by the glucose monitoring system 1 .

[0057] Figure 4 is a general flow chart showing a calibration method of the glucose monitoring system 1 according to an example of the present disclosure.

[0058] In some examples, such as Figure 4 As shown, the steps of calibrating the glucose monitoring system 1 may include: acquiring first data of the target object (step S100), determining the category to which the target object belongs based on the first data (step S200), determining a predicted baseline of the target object based on the category (step S300), acquiring second data of the target object (step S400), determining an actual baseline of the target object based on the second data (step S500), and calibrating the concentration value reading within a third time based on the predicted baseline and the actual baseline (step S600).

[0059] In some examples, the target object can be an animal or a simulated glucose environment. In other examples, the target object can be a human body (in this case, the target object can be called a user). For ease of understanding, the calibration method of the glucose monitoring system 1 is described below using the target object as a human body as an example. However, the specific real-time method of the present disclosure is not limited thereto, and unless there is a contradiction, the relevant description of the user also applies to the target object.

[0060] In some examples, the above calibration method can be used together with other calibration methods of the glucose monitoring system 1, such as the calibration method of the early signal attenuation (ESA).

[0061] For example, in some examples, the glucose monitoring system 1 may also include an early signal attenuation detection module. In some examples, the early signal attenuation detection module is used to detect whether early signal attenuation occurs. In some examples, the early signal attenuation detection module may detect whether early signal attenuation occurs based on the predicted baseline and the change in the glucose concentration value reading of the user after eating. In some examples, the early signal attenuation detection module may also use other methods to perform early signal attenuation detection.

[0062] In some examples, the second data may include a glucose concentration value reading obtained by the glucose monitoring system 1 over time during a second time. In some examples, the second time may be after the first time. In some examples, the third time may be after the second time.

[0063] In some examples, when the glucose monitoring system 1 is implanted in the body, the first time may be a time period having a first preset length after the glucose monitoring system 1 is implanted in the user's body. In some examples, the first time may be updated, see the relevant content of updating the prediction baseline for details. In some examples, the second time may be a time period having a second preset length after the first time. In some examples, the third time may be a time period including the current moment. In some examples, the third time may be a time period including the current moment and having a third preset length or within a certain range.

[0064] In some examples, in step S100, the user's first data may be obtained. In some examples, the first data may include a time-varying glucose concentration value reading obtained by the glucose monitoring system 1 within a first time. In some examples, the duration of the first time may be a preset value. In some examples, the first time may be a continuous time. In some examples, the start time of the first time may be reset. As described above, the calibration method involved in the present disclosure may be used after excluding the influence of early signal attenuation. That is, the first time may not include a time period in which there is early signal attenuation.

[0065] In some examples, in step S200, the classification to which the user belongs can be determined based on the first data. In some examples, the classification can be related to the control of the user's glucose concentration. In some examples, the control of the glucose concentration can include the characteristics of the fluctuation of the user's glucose concentration over time and the range of the user's glucose concentration. In this case, classifying the users based on the glucose control can better fit the concentration value distribution of the user's analyte when calibrating the glucose concentration value reading according to the classification, thereby more effectively calibrating the concentration value reading.

[0066] In some examples, in step S200, the classification to which the user belongs may include at least one of normal concentration, low concentration, too low concentration, and high concentration. In some examples, taking glucose as an example, the classification may include normal, low glucose concentration, too low glucose concentration, and high glucose concentration. Thus, the glucose concentration value reading can be calibrated based on a finer-grained classification.

[0067] In some examples, in step S200, the classification can be determined based on the waveform characteristics of the first data. In some examples, the waveform characteristics can refer to the characteristics of the fluctuation of the glucose concentration value reading over time. In some examples, the waveform characteristics can appear during and after a specific activity of the user. For example, eating, exercising, and sleeping. In this case, it is possible to determine the control situation of the user's glucose concentration based on the waveform characteristics and obtain the category to which the user belongs based on the control situation.

[0068] In some examples, in step S200, the waveform feature may include a rising amplitude, a falling amplitude, a rising rate, and a falling rate. In some examples, the waveform feature may be related to eating.

[0069] In some examples, in step S200, the waveform feature can be obtained by performing postprandial waveform recognition based on the waveform curve of the concentration value readings that vary with time obtained by the glucose monitoring system 1 at the first time. The waveform feature can include multiple different items, which can be expressed as P = {p1, p2, p3, ...}, where P represents the waveform feature, and p1, p2, p3, etc. represent multiple different items included in P.

[0070] In some examples, the waveform features may be the increase amplitude, decrease amplitude, increase rate and decrease rate of postprandial glucose concentration, and may also be other features. These waveform features are of great reference significance for determining the category to which the user belongs.

[0071] In some examples, the waveform features can also provide a reference for determining the physiological activity state of the user. The types of physiological activity states mentioned above may include whether the user is a diabetic, whether medication is used, and whether hypoglycemia occurs. The judgment results of these types are also of reference significance for determining the category to which the user belongs.

[0072] Figure 5 is a schematic flowchart showing the process of determining waveform features involved in the example of the present disclosure.

[0073] In some examples, such as Figure 5 As shown, the step of determining the category to which the user belongs may include: performing post-meal waveform recognition based on the first data to obtain a plurality of feature points (step S210), and determining waveform features based on the feature points (step S220).

[0074] In some examples, in step S210, a plurality of characteristic points may be obtained by performing postprandial waveform recognition based on the first data. That is, a plurality of characteristic points may be obtained based on the glucose concentration value reading at the first time. In some examples, the characteristic points may include fasting duration, postprandial peak point, rising period average point, and falling period average point, etc.

[0075] In some examples, the fasting duration may be a period of time from nighttime fasting to before a meal the next day, or may be the duration of a low value of the concentration value reading in a curve of the glucose concentration value reading over time (also referred to as a curve). In some examples, the postprandial peak point may be a point in the curve that is a high value of the concentration value reading.

[0076] In some examples, the rising period average point can be the average value of the concentration value reading during the period from the low value to the post-meal peak point in the curve, which can be expressed as Calculate, where x is the rising average point, a is the low value concentration reading before the glucose concentration rises, and b is the peak value concentration reading. In some examples, the falling average point can be the average value of the concentration reading from the peak point to the low value in the curve, which can be used Calculate, where y is the average value point of the decline period, b is the concentration value reading at the peak point, and c is the concentration value reading of the low value after the decline.

[0077] In some examples, the number of characteristic points may be a variation. In some examples, the number of characteristic points may increase over time. For example, in a glucose monitoring system, the glucose concentration value reading may be dynamically updated for one round according to a preset time interval, so that the number of characteristic points increases with the update. Thus, judging based on the increased number of characteristic points can improve the accuracy of judging the waveform characteristics.

[0078] In some examples, in step S220, the waveform feature may be determined based on the feature point. In some examples, the waveform feature may be determined based on the values ​​of multiple feature points. In other examples, the waveform feature may be determined based on the relationship between multiple feature points (e.g., the difference between feature points adjacent in time).

[0079] In some examples, the classification can be determined based on the degree of match between the waveform characteristics of the first data and the waveforms of glucose concentration values ​​corresponding to different types of people in existing data (such as data on glucose concentration values ​​changing over time based on statistics and research).

[0080] In some examples, if the waveform features of the user have a high degree of match with the waveform of the glucose concentration value of the population with normal glucose control, the user can be classified into the category corresponding to the population with normal glucose control. In some examples, if the waveform features of the user have a high degree of match with the waveform of the glucose concentration value of the population with high glucose control, the user can be classified into the category corresponding to the population with high glucose control.

[0081] In some examples, in step S300, the predicted baseline of the user can be determined based on the classification. In addition, the predicted baseline can be expressed as a range of analyte concentration values. In some examples, the classification and the predicted baseline can have a corresponding relationship. In some examples, the predicted baseline of the user can be determined based on the classification to which the user belongs and the corresponding relationship. That is, if the classification to which the user belongs changes, the predicted baseline of the user may also change. In some examples, the corresponding relationship may be a one-to-one corresponding relationship. In addition, the corresponding relationship may be predetermined. In some examples, the corresponding relationship may be a statistical value (e.g., an empirical value).

[0082] In some examples, the correspondence may be determined by a reference concentration value range. Specifically, the reference concentration value range may include multiple classification concentration value ranges, each classification concentration value range may correspond to each classification, and the prediction baseline corresponding to each classification is within the corresponding concentration value range.

[0083] For example, the classification includes at least one of normal concentration, low concentration, too low concentration and high concentration. Taking the reference concentration value range as an example, which may include a starting end value and an ending end value, the reference concentration value range may be divided into a first classification concentration value range, a second classification concentration value range, a third classification concentration value range and a fourth classification concentration value range corresponding to normal concentration, low concentration, too low concentration and high concentration, respectively.

[0084] Among them, the first classification concentration value range is a reference concentration value range, the second classification concentration value range and the third classification concentration value range can be in a range smaller than the starting end value, and the fourth classification concentration value range can be greater than the ending end value.

[0085] In some examples, the reference concentration value range can be determined by a representative range of glucose concentration values. In some examples, the representative range of glucose concentration values ​​can be determined for a population with normal glucose control conditions. Specifically, the range of glucose concentration values ​​of sample objects with normal control conditions can be statistically analyzed to determine the reference concentration value range.

[0086] In addition, further division of the classification concentration value range for low analyte concentrations can be determined based on the distribution of the range of glucose concentration values ​​of the sample objects for which the analyte concentration is low.

[0087] In some examples, the second classification concentration value range and the third classification concentration value range can be further divided and determined according to the range less than the starting end value and the control of the analyte concentration. In this case, by dividing the range of low analyte concentration more finely to improve the accuracy of calibration when the analyte concentration is low, it is possible to reduce the omission of abnormal events (e.g., hypoglycemia events) when the analyte concentration is low. In other examples, it is also possible not to divide, and merge the second classification concentration value range and the third classification concentration value range into one classification concentration value range.

[0088] Taking the specific reference concentration value range of 4 mmol / L to 5.5 mmol / L as an example, the first category concentration value range can be between 4 mmol / L and 5.5 mmol / L, the second category concentration value range can be between 3 mmol / L and 3.9 mmol / L, the third category concentration value range can be between 3 mmol / L and 3.9 mmol / L, and the fourth category concentration value range can be greater than 5.5 mmol / L.

[0089] In addition, the second classification concentration value range and the third classification concentration value range can be further divided and determined according to the range less than the starting end value and the control of the analyte concentration. In this case, by dividing the range of low analyte concentration more finely to improve the accuracy of calibration when the analyte concentration is low, it is possible to reduce the omission of abnormal events (e.g., hypoglycemia events) when the analyte concentration is low. In other examples, it is also possible not to divide, and merge the second classification concentration value range and the third classification concentration value range into one classification concentration value range.

[0090] In some examples, the category to which the user belongs may also be determined in combination with the user type (eg, a normal person and a diabetic patient) and whether the user has hypoglycemia.

[0091] Figure 6 Schematic diagram showing a glucose concentration value curve of an example individual in a population with normal glucose concentration control involved in the examples of the present disclosure.

[0092] In some examples, such as Figure 6As shown, for the example individual with normal glucose concentration control, the fluctuation of glucose concentration in the body will not exceed 7.8 mmol / L at most, and will not be less than 3.9 mmol / L at least. In addition, it can be seen from the figure that when the example individual is in a fasting state, the glucose concentration value generally presents a stable state, and the glucose concentration value can be considered to be stable at around 3.9 mmol / L or 4.0 mmol / L. At this time, the predicted baseline of such example individuals classified as normal (that is, the control of glucose concentration value is normal) can be determined based on 3.9 mmol / L or 4.0 mmol / L. It should be noted that the examples disclosed herein are not limited to this, and the above-mentioned numerical examples are for the convenience of explaining the example scheme disclosed herein, and the predicted baseline may also have other values.

[0093] In addition, in some examples, the user's predicted baseline can also be determined using a supervised learning method. Specifically, the waveform features of the glucose concentration data of people with different glucose concentration control conditions and the corresponding classification labels are used to train an artificial intelligence model based on supervised learning, and the waveform features of the user's first data are input into the trained artificial intelligence model to obtain the user's classification. The glucose concentration data includes glucose concentration value readings that change over time.

[0094] In some examples, in step S400, second data of the user may be obtained. In some examples, the second data includes a glucose concentration value reading obtained by the glucose monitoring system 1 over time during a second time, the second time being after the first time. In some examples, the start time of the second time may be reset. In some examples, the start time of the second time may be set after the start time of the first time is reset.

[0095] In some examples, in step S500, an actual baseline of the user may be determined based on the second data.

[0096] In some examples, in step S500, the actual baseline may be determined based on the concentration value readings within at least one reference period in which the fluctuation amplitude within the second time is less than the preset amplitude. In some examples, the fluctuation amplitude may refer to the difference between the maximum value and the minimum value of the concentration value readings within a period of time. In some examples, the reference period may refer to a preset sampling period for determining the actual baseline. Thus, a relatively stable actual baseline can be obtained.

[0097] In some examples, if there is only one reference cycle, the actual baseline can be determined based on the concentration value readings in the reference cycle. In some examples, if there are multiple reference cycles, the actual baseline can also be determined based on the concentration value readings in a reference cycle with the smallest fluctuation amplitude among the multiple reference cycles.

[0098] Figure 7is a schematic diagram showing a glucose concentration value reading for determining an actual baseline of a user according to an example of the present disclosure.

[0099] In some examples, such as Figure 7 As shown, a curve of the change of the nano concentration value reading of the user's glucose over time is obtained by the user's second data. It can be seen from the figure that when the time is 0 to 6 o'clock, the fluctuation amplitude of the user's glucose is small, between 3.8 mmol / L and 4.1 mmol / L. At this time, the preset amplitude can be 0.3 mmol / L, and the reference period can be 0 to 6 o'clock. It should be noted that the examples disclosed in this disclosure are not limited to this. The above numerical examples are cited for the convenience of explaining the example scheme of the disclosure, and the preset amplitude and the reference period may also have other values.

[0100] In some examples, in step S500, the actual baseline may be determined based on the statistical values ​​of the concentration value readings within the reference period. In some examples, the statistical values ​​may include an average, a median, a mode, and the like.

[0101] In some examples, in step S500, a fitting equation may be obtained based on the concentration value readings in the reference period, and the actual baseline may be determined using the fitting equation. In some examples, the fitting may be a linear fitting.

[0102] In some examples, the calibration method may further include updating the predicted baseline. In this case, updating the predicted baseline can adapt the calibration to the change in the trend of the user's glucose concentration value, and can improve the accuracy of the calibration. Specifically, the first data may be updated to obtain the updated classification to which the user belongs, and then the predicted baseline of the user is determined based on the updated classification. For details, see the relevant descriptions in steps S100, S200, and S300.

[0103] In some examples, the method of updating the prediction baseline may include at least one of updating the prediction baseline periodically, updating the prediction baseline in response to an update request, and updating the prediction baseline in response to triggering a preset condition. In some examples, the method of updating the prediction baseline may include multiple methods mentioned above at the same time. In this case, using multiple methods to update the prediction baseline can be more flexible in that different methods can be used to update the prediction baseline. In addition, in this case, the prediction baseline can be updated under different conditions.

[0104] In some examples, the method of regularly updating the predicted baseline can update the predicted baseline according to a preset update cycle. In some examples, the update cycle can include at least one cycle of one day, one week, and 12 hours. Preferably, the update cycle can be one day. In some examples, the method of regularly updating the predicted baseline can update the predicted baseline for a control cycle (e.g., a diagnosis and treatment cycle) for the user's glucose concentration. Thus, the predicted baseline can be updated at a stable frequency.

[0105] In some examples, the predicted baseline may be updated in response to an update request by the user through a client or server associated with the glucose monitoring system 1. This allows the user to have a higher degree of control.

[0106] In some examples, in response to triggering a preset condition, the preset condition may be that the difference between the waveform feature of the second data and the waveform feature of the first data is greater than a preset degree, thereby enabling the update of the prediction baseline to be more timely.

[0107] In some examples, the degree of difference between the waveform features of the second data and the waveform features of the first data can be obtained by performing postprandial waveform recognition on the first data and the second data and comparing the difference in the waveform features between the data. In other examples, the degree of difference can be obtained by determining the classification of the first data and the second data and comparing the difference between the classifications.

[0108] In some examples, in step S600, the concentration value reading within the third time can be calibrated based on the predicted baseline and the actual baseline. In some examples, the third time is after the second time. In some examples, the adjustment direction and adjustment range of the concentration value reading within the third time can be determined based on the deviation between the actual baseline and the predicted baseline. In this case, the deviation-based method is relatively simple and can easily determine the adjustment direction and adjustment range.

[0109] Figure 8 is a schematic flow chart showing the calibration of concentration value readings based on predicted baseline and actual baseline involved in examples of the present disclosure.

[0110] In some examples, such as Figure 8 As shown, the step of calibrating the concentration value reading based on the predicted baseline and the actual baseline includes determining the adjustment direction and adjustment amplitude of the concentration value reading based on the deviation between the actual baseline and the predicted baseline (step S610), identifying whether an abnormal analyte concentration event occurs (step S620), and adjusting the concentration value reading based on the adjustment direction, adjustment amplitude and identification result (step S630).

[0111] In some examples, in step S610, the adjustment direction and adjustment range of the concentration value reading can be determined based on the deviation between the actual baseline and the predicted baseline. Specifically, if the actual baseline is 0.4 mmol / L lower than the predicted baseline, it can be determined that the adjustment direction of the glucose concentration value reading in the third time is upward adjustment, and the adjustment range is 0.4 mmol / L. It should be noted that the examples of the present disclosure are not limited to this, and the above numerical values ​​are cited for the convenience of explaining the example scheme of the present disclosure, and the adjustment direction and adjustment range may also have other values.

[0112] In some examples, in step S610, a step size may also be set for the adjustment amplitude. Specifically, considering the importance of glucose concentration in the body, aggressive concentration value reading adjustment may cause inaccurate concentration value reading or excessive fluctuation, so a multiple adjustment method may be adopted after obtaining the deviation between the actual baseline and the predicted baseline, and a step size may be set for the adjustment amplitude. In some examples, the step size may be an upper limit of the adjustment amplitude for each adjustment. In some examples, the step size of the adjustment amplitude may be a fixed value. In some examples, the step size of the adjustment amplitude may be a non-fixed value.

[0113] In some examples, in step S620, it is possible to identify whether an abnormal analyte concentration event occurs. Specifically, in some examples, it is possible to identify whether an abnormal glucose concentration event occurs within the third time. In some examples, an abnormal glucose concentration event may include a glucose concentration that is too low and a glucose concentration that is too high. If an abnormal glucose concentration event is identified, an upper limit or a lower limit may be set for the range of the adjustment amplitude.

[0114] That is, when an abnormal concentration event is identified within the third time, an upper limit or a lower limit is set for the range of the adjustment amplitude. For example, when the adjustment direction is downward, a lower limit is set for the range of the adjustment amplitude; when the adjustment direction is upward, an upper limit is set for the range of the adjustment amplitude. In this case, setting an upper limit or a lower limit for the range of the adjustment amplitude for an abnormal analyte concentration event can improve the sensitivity to the abnormal analyte concentration event.

[0115] In particular, if the abnormal analyte concentration event is an event in which the analyte concentration value reading within the third time is lower than the preset concentration value, an upper limit is set for the range of the adjustment amplitude. Specifically, in some examples, considering that hypoglycemia will have a greater impact on the normal functioning of the human body, when the identified abnormal glucose concentration event is a glucose concentration value reading lower than the preset concentration value reading, an upper limit is set for the range of the adjustment amplitude. Thus, the sensitivity to the situation where the analyte concentration is too low can be improved. In addition, the probability of underreporting of hypoglycemia events can also be reduced.

[0116] In some examples, in step S630, the concentration value reading may be adjusted based on the adjustment direction, adjustment amplitude, and recognition result. Specifically, if the recognition result in step S620 is that there is an abnormal concentration event and the upper or lower limit of the adjustment amplitude is set, the concentration value reading is adjusted based on the adjustment direction and adjustment range determined in step S610 without exceeding the upper or lower limit. If the recognition result in step S620 is that there is no abnormal concentration event, the concentration value reading is adjusted based on the adjustment direction and adjustment range determined in step S610.

[0117] In some examples, the glucose concentration information obtained by the electronic system 3 can be sent out via wireless communication such as Bluetooth, Wi-Fi, etc. An external reading device such as a mobile phone or a computer can receive the glucose concentration information sent by the electronic system 3 and display the glucose concentration.

[0118] In summary, in the calibration method (also referred to as the calibration method) of the analyte monitoring system involved in the disclosed example, the concentration value reading of the analyte of the analyte monitoring system can be calibrated based on the classification to which the target object belongs. In this case, calibrating the concentration value reading based on the classification to which the target object itself belongs can reduce the dependence on external calibration equipment, thereby improving the convenience of calibration. In addition, the present disclosure uses the data obtained by the analyte monitoring system for calibration, which can improve the integration of the present disclosure with the analyte monitoring system.

[0119] In addition, the example of the present disclosure further provides a storage medium, the storage medium stores computer program instructions, and when the processor runs the computer program instructions, at least one step in the above calibration method is executed. In this case, the present disclosure can be applied to electronic devices that can run computer programs.

[0120] In addition, the example of the present disclosure also provides an analyte monitoring system, including an analyte sensor and an electronic device connected to the analyte sensor, the electronic device including a processor and the above-mentioned storage medium related to the calibration method. In this case, the present disclosure can be applied to an analyte monitoring system that can run a computer program, thereby enabling the analyte monitoring system to obtain more accurate analyte concentration information.

[0121] According to the present disclosure, a calibration method, storage medium and related system of an analyte monitoring system are provided, which can reduce the dependence on external calibration equipment and improve the convenience of calibration.

[0122] Although the present disclosure is specifically described above in conjunction with the accompanying drawings and examples, it is to be understood that the above description does not limit the present disclosure in any form. Those skilled in the art may modify and change the present disclosure as needed without departing from the essential spirit and scope of the present disclosure, and these modifications and changes all fall within the scope of the present disclosure.

Claims

1. A method for calibrating an analyte monitoring system, characterized in that: include: Acquire first data of a target object, the first data comprising a concentration value reading of an analyte acquired by the analyte monitoring system over time within a first time period; Determine the category to which the target object belongs based on the first data; determine a prediction baseline for the target object based on the category; Acquiring second data of the target object, the second data comprising a concentration value reading of the analyte acquired by the analyte monitoring system over time at a second time, the second time being after the first time; An actual baseline of the target object is determined based on the second data; and a concentration value reading within a third time is calibrated based on the predicted baseline and the actual baseline, the third time being after the second time.

2. The calibration method according to claim 1, characterized in that: The classification is related to the control status of the analyte concentration of the target object.

3. The calibration method according to claim 2, characterized in that: The classification includes normal concentration, low concentration, too low concentration and high concentration.

4. The calibration method according to claim 1, characterized in that: The classification is determined based on waveform features of the first data.

5. The calibration method according to claim 4, characterized in that: The waveform characteristics include rising amplitude, falling amplitude, rising rate and falling rate, and the waveform characteristics are related to eating.

6. The calibration method according to claim 1 or 5, characterized in that: It also includes updating the prediction baseline periodically, updating the prediction baseline in response to an update request, or updating the prediction baseline in response to a difference between the waveform feature of the second data and the waveform feature of the first data being greater than a preset degree.

7. The calibration method according to claim 1, characterized in that: The actual baseline is determined based on concentration value readings in at least one reference period in which the fluctuation amplitude in the second time is smaller than a preset amplitude.

8. The calibration method according to claim 1, characterized in that: In the calibration, the adjustment direction and adjustment amplitude of the concentration value reading within the third time are determined based on the deviation between the actual baseline and the predicted baseline.

9. The calibration method according to claim 8, characterized in that: When an abnormal analyte concentration event is identified within the third time, an upper limit or a lower limit is set for the range of the adjustment amplitude.

10. The calibration method according to claim 9, characterized in that: When the abnormal analyte concentration event is an event in which the analyte concentration value reading within the third time is lower than a preset concentration value, an upper limit is set for the range of the adjustment amplitude.

11. The calibration method according to claim 1, characterized in that: The analytes include one or more of blood ketones, acetylcholine, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase, creatine, creatinine, DNA, fructosamine, glucose, glutamine, growth hormone, hormones, ketone bodies, lactate, peroxide, prostate specific antigen, prothrombin, RNA, thyroid stimulating hormone and troponin.

12. A storage medium, characterized in that: The storage medium stores computer program instructions, and when the processor runs the computer program instructions, the calibration method according to any one of claims 1 to 11 is executed.

13. An analyte monitoring system, characterized in that: The device comprises an analyte sensor and an electronic device connected to the analyte sensor, wherein the electronic device comprises a processor and the storage medium as claimed in claim 11.